DaVita Inc. (NYSE:DVA) Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale raised its holdings in DaVita Inc. (NYSE:DVA) by 25.2% during the 4th quarter, Holdings Channel reports. The firm owned 11,428 shares of the company’s stock after buying an additional 2,298 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in DaVita were worth $1,186,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Norges Bank purchased a new position in DaVita in the 4th quarter valued at about $116,373,000. Deutsche Bank AG lifted its position in shares of DaVita by 421.8% in the third quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after acquiring an additional 885,195 shares in the last quarter. Amundi boosted its stake in shares of DaVita by 226.3% in the fourth quarter. Amundi now owns 659,372 shares of the company’s stock worth $52,592,000 after acquiring an additional 457,285 shares during the last quarter. Morgan Stanley increased its position in shares of DaVita by 37.9% during the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after purchasing an additional 339,051 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in DaVita by 912.4% in the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock valued at $25,249,000 after purchasing an additional 304,739 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

DaVita stock opened at $130.42 on Monday. The stock has a market cap of $11.44 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 1.16 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The firm has a 50 day simple moving average of $128.95 and a 200-day simple moving average of $108.05. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $141.54.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter last year, the firm earned $1.11 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts expect that DaVita Inc. will post 9.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on DVA shares. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 8th. UBS Group boosted their price target on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Truist Financial raised their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Barclays started coverage on DaVita in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target for the company. Finally, TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the transaction, the insider now owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total value of $1,362,438.05. Following the sale, the insider now owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 134,540 shares of company stock worth $16,551,071. Company insiders own 1.40% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.